Toggle light / dark theme

A Machine‐Learning Approach Identifies Rejuvenating Interventions in the Human Brain

As the world population is ageing rapidly, with over two billion people projected to be above the age of 60 by 2050, age-related brain disorders are on the rise. Living longer but in poor health is not only a daunting prospect, it also places a substantial burden on healthcare systems worldwide. The idea of being able to counteract the functional decline of our brain through rejuvenating interventions sounds therefore promising. The question is how can we identify compounds that have the potential to efficiently rejuvenate brain cells and to protect the ageing population from neurodegeneration? Prof. Antonio Del Sol and his teams of computational biologists, based both at the LCSB from the University of Luxembourg and at the CIC bioGUNE in Bilbao, used their machine learning expertise to tackle the challenge.

The researchers developed what is called an “ageing clock”, a computational tool designed to measure the biological age of cells, as opposed to their chronological age. Indeed, the organs and tissues of people of the same age can evolve differently over time depending on genetic and environmental factors, leading to different biological ages. These clocks are therefore useful tools to assess ageing at the molecular level and can help in understanding its causes and consequences.

The clock designed by the LCSB and CIC bioGune researchers is specific to the brain and uses gene expression information from 365 genes to make predictions. Using a machine learning approach, it was trained on data from healthy individuals, aged from 20 to 97, and could accurately predict their age. Further tests showed that the clock is able to estimate the biological age of different cell types in the brain, especially neurons. Lastly, by looking at the predicted biological ages for healthy individuals and for patients with neurological conditions, the researchers observed that patients exhibited a higher biological age.

“Our results tell us that the biological age of the brain cells calculated by our clock reflects the decline in brain function experienced by the patients, especially between 60 and 70, and is even correlated with the degree of neurodegeneration,” explains Dr Guillem Santamaria, first author of the study. “It supports the view of neurodegeneration as a form of accelerated ageing but, more importantly, the positive association between neurodegeneration and biological age suggests that the rejuvenating interventions identified by the clock could serve as neuroprotective agents.”

The aim of the researchers was to use the clock to find genetic or chemical interventions that would significantly shift back the biological age of brain cells. They explored the effect of thousands of compounds on neural progenitor cells and neurons and identified 453 unique rejuvenating interventions.

Among the identified compounds that have the potential to reverse the biological age of the two types of brain cells, several are known to extend lifespan in animal models and some are already used to treat neurological disorders, but the vast majority has not yet been studied in the context of health-or lifespan extension. “On the one hand, the fact that our computational platform identified drugs that have a known effect on brain function supports the idea that using the predicted effect of a compound on the biological age is an efficient way to evaluate its neuroprotective potential,” details Prof. Antonio Del Sol, head of the Computational Biology groups at the LCSB and CIC BioGUNE. “On the other, the results also highlight that our clock can help us find many new candidates that haven’t been studied before for their rejuvenating properties. It opens up a lot of new avenues.”

As a proof of concept of their approach, the researchers then tested three of the predicted compounds in mice, in collaboration with the team of Prof. Rubén Nogueiras at the Centre for Research in Molecular Medicine and Chronic Diseases. The administration of these drugs significantly reduced anxiety and slightly increased spatial memory in older mice, addressing two well-known symptoms associated with ageing. An analysis of gene expression showed that the combination of these compounds also led to a shift toward a younger phenotype. Altogether, these results show that a selection of compounds predicted to rejuvenate the brain did produce rejuvenation at the molecular level in the cortex of aged mice and had an impact on behavioural and cognitive functions.

Globally, the study, recently published in the journal Advanced Science, highlights the computational ageing clock developed by the researchers as a valuable resource for identifying brain-rejuvenating interventions with therapeutic potential in neurodegenerative diseases. It provides a strong foundation for further research. “The hundreds of compounds predicted by our platform require validation across multiple biological systems to assess their efficacy and safety, offering extensive opportunities for future therapeutic development,” concludes Prof. Antonio Del Sol.

Tesla’s Biggest FSD Problem Isn’t Technical

Questions to inspire discussion.

Marketing and Promotion.

📣 Q: What marketing strategies should Tesla employ to promote FSD? A: Tesla should invest in advertising, highlighting the cost-effectiveness of their vehicles, and invite influencers and press for a special day to meet the AI team and spread the word about FSD.

Technical Advancements.

🧠 Q: What future improvements are planned for Tesla’s FSD? A: Tesla plans to expand FSD capabilities with 10x parameters in future iterations, making it an even more valuable feature and key brand differentiator.

Safety Benefits.

Outbreak of Chikungunya Virus Poses Global Risk, Warns WHO

The World Health Organization warned on Tuesday a major chikungunya virus epidemic risks sweeping around the globe, calling for urgent action to prevent it.

The WHO said it was picking up exactly the same early warning signs as in a major outbreak two decades ago and wanted to prevent a repeat.

Chikungunya is a mosquito-borne viral disease that causes fever and severe joint pain, which is often debilitating. In some cases it can be deadly.

Macquarie University’s new study shows DNA ‘glue’ could help prevent and treat age related disorders

Macquarie University new study could hold the key to developing therapies for devastating age-related diseases such as motor neuron disease (MND), Alzheimer’s disease, and Parkinson’s disease.

The research at Macquarie University conducted by neurobiologist, Dr. Sina Shadfar and colleagues in the Motor Neuron Disease Research Centre, reveals a protein called protein disulphide isomerase (PDI) helps repair serious deoxyribonucleic acid (DNA) damage. This breakthrough opens new possibilities for therapies aimed at boosting the body’s ability to fix its own DNA, a process that becomes less efficient as we age.

Dr. Shadfar, Associate, Macquarie Medical School stated “Brain cells are very vulnerable. Unlike skin or blood cells, they don’t divide or renew so any damage that builds up in them stays and if the damage isn’t repaired, it can eventually lead to the death of these critical cells.”

Genetic variants linked with higher risk of developing bipolar disorder

Bipolar disorder is a mental health condition characterized by extreme mood swings, with alternating periods of depression and manic episodes. Past research suggests that bipolar disorder has a strong genetic component and is among the most heritable psychiatric disorders.

To better understand the that increase the risk of developing this mental health disorder, neuroscientists and geneticists have carried out various genome-wide association studies (GWAS). These are essentially studies aimed at identifying specific regions of the human genome that are linked with an increased risk of having bipolar disorder, also referred to as bipolar risk loci.

While earlier works have identified many of these regions, causal single nucleotide polymorphisms (SNPs) for the disorder are largely unknown. These are essentially genetic variants that primarily contribute to bipolar disorder risk, as opposed to just being mere markers of it.

Coordinated defect arrangement shown to boost superconductivity in new study

An international team of scientists, including physicists from HSE MIEM, has demonstrated that when defects within a material are arranged in a specific pattern rather than randomly, superconductivity can occur at a higher temperature and extend throughout the entire material. This discovery could help develop superconductors that operate without the need for extreme cooling.

The study has been published in Physical Review B.

Superconductivity is a state in which electric current flows through a material without any . In conventional conductors, part of the energy is converted into heat, but in superconductors, this does not occur—current flows freely and does not weaken. Today, superconductors are used in applications such as MRI machines, where superconducting coils generate strong magnetic fields.

Stowaways in the cargo: Contaminating nucleic acids in rAAV preparations for gene therapy

A useful review on the nucleic acid contaminants found in AAVs, how to detect such contaminants, their biological implications, and how we can minimize nucleic acid contaminants in the future through new manufacturing innovations! #biotech #genetherapy


Brimble and colleagues review nucleic acid heterogeneity of rAAV for gene therapy. Alongside the intended expression cassette, non-therapeutic DNA is present within rAAV preparations. These contaminants can be transferred and can even expressed after delivery. They discuss sources of DNA contamination in rAAV and highlight existing strategies to improve vector purity.

Bernoulli family

Originally from Antwerp, a branch of the family relocated to Basel in 1620. [ 4 ] While their origin in Antwerp is certain, proposed earlier connections with the Dutch family of Italian ancestry called Bornouilla (Bernoullie), or with the Castilian family de Bernuy (Bernoille, Bernouille), are uncertain. [ 4 ]

The first known member of the family was Leon Bernoulli (d. 1561), a doctor in Antwerp, at that time part of the Spanish Netherlands. His son, Jacob, emigrated to Frankfurt am Main in 1570 to escape from the Spanish persecution of the Protestants. Jacob’s grandson, a spice trader, also named Jacob, moved to Basel, Switzerland in 1620, and was granted citizenship in 1622. [ 4 ] His son, Niklaus Bernoulli [de] (Nicolaus, 1623–1708), Leon’s great-great-grandson, married Margarethe Schönauer.

[ edit ].

Brain Plasticity Modulator p75 Neurotrophin Receptor in Human Urine after Different Acute Brain Injuries—A Prospective Cohort Study

Acute brain injuries (ABIs) pose a substantial global burden, demanding effective prognostic indicators for outcomes. This study explores the potential of urinary p75 neurotrophin receptor (p75NTR) concentration as a prognostic biomarker, particularly in relation to unfavorable outcomes. The study involved 46 ABI patients, comprising sub-cohorts of aneurysmal subarachnoid hemorrhage, ischemic stroke, and traumatic brain injury. Furthermore, we had four healthy controls. Samples were systematically collected from patients treated at the University Hospital of Turku between 2017 and 2019, at early (1.50 ± 0.70 days) and late (9.17 ± 3.40 days) post-admission time points. Urinary p75NTR levels, measured by ELISA and normalized to creatinine, were compared against patients’ outcomes using the modified Rankin Scale (mRS). Early urine samples showed no significant p75NTR concentration difference between favorable and unfavorable mRS groups. In contrast, late samples exhibited a statistically significant increase in p75NTR concentrations in the unfavorable group (p = 0.033), demonstrating good prognostic accuracy (AUC = 70.9%, 95% CI = 53–89%, p = 0.03). Assessment of p75NTR concentration changes over time revealed no significant variation in the favorable group (p = 0.992) but a significant increase in the unfavorable group (p = 0.009). Moreover, p75NTR concentration was significantly higher in ABI patients (mean ± SD 40.49 ± 28.83–65.85 ± 35.04 ng/mg) compared to healthy controls (mean ± SD 0.54 ± 0.44 ng/mg), irrespective of sampling time or outcome (p < 0.0001). In conclusion, late urinary p75NTR concentrations emerged as a potential prognostic biomarker for ABIs, showing increased levels associated with unfavorable outcomes regardless of the specific type of brain injury. While early samples exhibited no significant differences, the observed late increases emphasize the time-dependent nature of this potential biomarker. Further validation in larger patient cohorts is crucial, highlighting the need for additional research to establish p75NTR as a reliable prognostic biomarker across various ABIs. Additionally, its potential role as a diagnostic biomarker warrants exploration.

/* */